Multidimensional COPD Prognostic Tool • Celli et al.
BMI
FEV1 % Predicted
mMRC Grade
6MWD (Meters)
Ready for Assessment
Complete all metrics to determine multidimensional COPD severity.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Prognostic assessment of patients with chronic obstructive pulmonary disease (COPD).
To predict 4-year survival and risk of hospitalization.
As part of the evaluation for lung volume reduction surgery (LVRS) or lung transplantation.
To guide palliative care discussions and advanced care planning in end-stage lung disease.
Section 2
Formula & Logic
The BODE Variables
B: BMI
Nutritional status (BMI ≤ 21 indicates higher risk)
O: Obstruction
Severity of airflow limitation (% predicted FEV1)
D: Dyspnea
Symptom burden using the modified MRC scale
E: Exercise
Functional capacity (6-minute walk distance)
mMRC Dyspnea Scale
Grade 0: Breathless only with strenuous exercise.
Grade 1: Short of breath when hurrying on level ground or walking up a slight hill.
Grade 2: Walks slower than people of same age on level ground due to breathlessness.
Grade 3: Stops for breath after walking about 100 meters or after a few minutes on level ground.
Grade 4: Too breathless to leave the house or breathless when dressing.
Section 3
Pearls/Pitfalls
Superiority to FEV1 Alone
While FEV1 is the standard for COPD staging (GOLD), the BODE Index is a better predictor of the risk of death. It captures the systemic nature of COPD, including muscle wasting and functional decline.
Palliative Thresholds
A BODE score of 7–10 is associated with a 4-year mortality of approximately 80%.
A decline in BODE score over time (even without change in FEV1) indicates a significant increase in mortality risk.
Section 4
Evidence Appraisal
Primary Derivation
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
Celli BR et al. • N Engl J Med.. 2004;n=207. Demonstrated that the BODE index is a better predictor of mortality than the FEV1.
Origins
Developed by Dr. Bartolome Celli and his team. It was the first widely accepted multidimensional staging system in respiratory medicine, shifting the focus from simple spirometry to the "whole patient" impact of lung disease.
